Chronic Pain - Pipeline Review, H2 2016

  • ID: 3927201
  • Report
  • 335 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics, LLC
  • Cyclenium Pharma, Inc.
  • Heron Therapeutics, Inc.
  • MD Biosciences GmbH
  • Pain Therapeutics, Inc.
  • MORE
Chronic Pain - Pipeline Review, H2 2016

Summary

‘Chronic Pain - Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain
- The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
- The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics, LLC
  • Cyclenium Pharma, Inc.
  • Heron Therapeutics, Inc.
  • MD Biosciences GmbH
  • Pain Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Chronic Pain Overview

Therapeutics Development

Pipeline Products for Chronic Pain - Overview

Pipeline Products for Chronic Pain - Comparative Analysis

Chronic Pain - Therapeutics under Development by Companies

Chronic Pain - Therapeutics under Investigation by Universities/Institutes

Chronic Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Chronic Pain - Products under Development by Companies

Chronic Pain - Products under Investigation by Universities/Institutes

Chronic Pain - Companies Involved in Therapeutics Development

AbbVie Inc

Acadia Pharmaceuticals Inc.

Adynxx, Inc.

Allergan Plc

Amorsa Therapeutics Inc.

arGEN-X BV

Asana BioSciences, LLC

AskAt Inc.

Astraea Therapeutics, LLC

Axsome Therapeutics, Inc.

BioDelivery Sciences International, Inc.

Biogen Inc

Bionomics Limited

Camurus AB

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

ChironWells GmbH

Collegium Pharmaceutical, Inc.

Crinetics Pharmaceuticals, Inc.

Cyclenium Pharma, Inc.

Cytogel Pharma, LLC

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Dompe Farmaceutici S.p.A.

Echo Pharmaceuticals B.V.

Egalet Corporation

Eli Lilly and Company

Elite Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Heron Therapeutics, Inc.

INSYS Therapeutics, Inc.

Johnson & Johnson

Kareus Therapeutics, SA

KPI Therapeutics, Inc.

Kymab Limited

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Lpath, Inc.

MD Biosciences GmbH

Merck & Co., Inc.

Moberg Pharma AB

Mundipharma International Ltd

Nanomerics Ltd

Nektar Therapeutics

Neura Therapeutik, LLC

Orion Oyj

Pacira Pharmaceuticals, Inc.

Pain Therapeutics, Inc.

PeriphaGen, Inc.

Pfizer Inc.

Phosphagenics Limited

Prismic Pharmaceuticals, Inc.

Purdue Pharma LP

Relmada Therapeutics, Inc.

Ribomic Inc.

Sea4Us

Shulov Innovative Science Ltd.

Synactix Pharmaceuticals, Inc.

Syntrix Biosystems, Inc.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd.

Trevena, Inc.

Voyager Therapeutics, Inc.

Yooyoung Pharmaceutical Co., Ltd.

Zynerba Pharmaceuticals, Inc.

Chronic Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(celecoxib + tramadol hydrochloride) - Drug Profile

(hydrocodone bitartrate + palmidrol) - Drug Profile

(morphine sulfate + palmidrol) - Drug Profile

(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile

(oxycodone hydrochloride + palmidrol) - Drug Profile

(palmidrol + pregabalin) - Drug Profile

A-200 - Drug Profile

AGN-XX - Drug Profile

AGN-YY - Drug Profile

AMS-520 - Drug Profile

ASN-008 - Drug Profile

AVLX-144 - Drug Profile

AXS-06 - Drug Profile

AYX-1 - Drug Profile

AYX-2 - Drug Profile

BBI-11008 - Drug Profile

bupivacaine - Drug Profile

bupivacaine hydrochloride - Drug Profile

buprenorphine hydrochloride - Drug Profile

buprenorphine hydrochloride depot - Drug Profile

buprenorphine hydrochloride ER - Drug Profile

buprenorphine hydrochloride long acting - Drug Profile

cebranopadol - Drug Profile

cetirizine hydrochloride + cromolyn sodium - Drug Profile

cetuximab - Drug Profile

CNTX-0290 - Drug Profile

CNV-3000164 - Drug Profile

CNV-3000223 - Drug Profile

CR-4056 - Drug Profile

CR-701 - Drug Profile

CRB-0089 - Drug Profile

Cyt-1010 - Drug Profile

dexmedetomidine hydrochloride - Drug Profile

DF-2593A - Drug Profile

difelikefalin - Drug Profile

dronabinol - Drug Profile

DS-1971 - Drug Profile

DWJ-208 - Drug Profile

ECP-1014 - Drug Profile

Egalet-003 - Drug Profile

fluticasone propionate - Drug Profile

FY-101C - Drug Profile

FY-103B - Drug Profile

GBR-900 - Drug Profile

Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile

grapiprant - Drug Profile

HPI-201 - Drug Profile

HS-731 - Drug Profile

hydrocodone bitartrate ER - Drug Profile

hydrocodone bitartrate ER - Drug Profile

hydrocodone bitartrate ER - Drug Profile

hydromorphone hydrochloride - Drug Profile

Kindolor - Drug Profile

KY-1017 - Drug Profile

L-779976 - Drug Profile

lacosamide - Drug Profile

LEVI-04 - Drug Profile

levorphanol tartrate ER - Drug Profile

Lpathomab - Drug Profile

MD-354 - Drug Profile

Monoclonal Antibodies for Chronic Pain - Drug Profile

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile

morphine sulfate ER - Drug Profile

MR-309 - Drug Profile

NET-END - Drug Profile

NKTR-181 - Drug Profile

NL-001 - Drug Profile

NL-002 - Drug Profile

NM-0127 - Drug Profile

Omnitram - Drug Profile

onabotulinumtoxin A - Drug Profile

OSX-300 - Drug Profile

OSX-300 Backups - Drug Profile

oxycodone hydrochloride ER - Drug Profile

oxycodone hydrochloride ER - Drug Profile

oxycodone hydrochloride ER - Drug Profile

oxymorphone hydrochloride - Drug Profile

oxymorphone hydrochloride ER - Drug Profile

PAC-CP - Drug Profile

palmidrol - Drug Profile

Peptide to Block Cav2.2 for CNS Disorders - Drug Profile

Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

PN-6047 - Drug Profile

PRC-062 - Drug Profile

Prostatic Acid Phosphatase - Drug Profile

PspTx-3 - Drug Profile

raxatrigine hydrochloride - Drug Profile

RBM-005 - Drug Profile

REL-1017 - Drug Profile

SAFit2 - Drug Profile

Small Molecule for Chronic Pain - Drug Profile

Small Molecule for Chronic Pain - Drug Profile

Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile

Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile

Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile

Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile

Small Molecules for Chronic Wound Pain - Drug Profile

Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile

Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile

Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile

Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile

Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile

Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile

Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile

Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile

Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile

Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile

Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile

Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile

SYN-003 - Drug Profile

Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile

tanezumab - Drug Profile

tapentadol hydrochloride IR - Drug Profile

TRV-734 - Drug Profile

U-2902 - Drug Profile

UMB-425 - Drug Profile

Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile

VM-902A - Drug Profile

VYNAV-01 - Drug Profile

XT-101 - Drug Profile

YYC-301 - Drug Profile

ZEP-3 - Drug Profile

ZYN-001 - Drug Profile

Chronic Pain - Dormant Projects

Chronic Pain - Discontinued Products

Chronic Pain - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Chronic Pain, H2 2016

Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Development by Companies, H2 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Investigation by Universities/Institutes, H2 2016

Chronic Pain - Pipeline by AbbVie Inc, H2 2016

Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016

Chronic Pain - Pipeline by Adynxx, Inc., H2 2016

Chronic Pain - Pipeline by Allergan Plc, H2 2016

Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016

Chronic Pain - Pipeline by arGEN-X BV, H2 2016

Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016

Chronic Pain - Pipeline by AskAt Inc., H2 2016

Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016

Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016

Chronic Pain - Pipeline by Biogen Inc, H2 2016

Chronic Pain - Pipeline by Bionomics Limited, H2 2016

Chronic Pain - Pipeline by Camurus AB, H2 2016

Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016

Chronic Pain - Pipeline by ChironWells GmbH, H2 2016

Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016

Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016

Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016

Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016

Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016

Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016

Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016

Chronic Pain - Pipeline by Egalet Corporation, H2 2016

Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016

Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016

Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016

Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016

Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by Johnson & Johnson, H2 2016

Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016

Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by Kymab Limited, H2 2016

Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016

Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016

Chronic Pain - Pipeline by Lpath, Inc., H2 2016

Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016

Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016

Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016

Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016

Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016

Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016

Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016

Chronic Pain - Pipeline by Orion Oyj, H2 2016

Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016

Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016

Chronic Pain - Pipeline by Pfizer Inc., H2 2016

Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016

Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016

Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016

Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by Ribomic Inc., H2 2016

Chronic Pain - Pipeline by Sea4Us, H2 2016

Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016

Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016

Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016

Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016

Chronic Pain - Pipeline by Trevena, Inc., H2 2016

Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016

Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016

Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Chronic Pain - Dormant Projects, H2 2016

Chronic Pain - Dormant Projects (Contd..1), H2 2016

Chronic Pain - Dormant Projects (Contd..2), H2 2016

Chronic Pain - Dormant Projects (Contd..3), H2 2016

Chronic Pain - Dormant Projects (Contd..4), H2 2016

Chronic Pain - Dormant Projects (Contd..5), H2 2016

Chronic Pain - Dormant Projects (Contd..6), H2 2016

Chronic Pain - Dormant Projects (Contd..7), H2 2016

Chronic Pain - Dormant Projects (Contd..8), H2 2016

Chronic Pain - Discontinued Products, H2 2016

Chronic Pain - Discontinued Products (Contd..1), H2 2016

Chronic Pain - Discontinued Products (Contd..2), H2 2016 325List of Figures

Number of Products under Development for Chronic Pain, H2 2016

Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics, LLC
  • Cyclenium Pharma, Inc.
  • Heron Therapeutics, Inc.
  • MD Biosciences GmbH
  • Pain Therapeutics, Inc.
  • MORE
Chronic Pain Chronic pain is an abnormal processing of pain where the original injury or cause of acute pain has resolved, but the warning system has failed to shut off. Chronic pain may originate with an initial trauma/injury or infection, or there may be an ongoing cause of pain. Symptoms include fatigue, sleeplessness, weakened immune system and disability. Medications (pain relievers), nerve blocks, or surgery are some treatments used for chronic pain.

Chronic Pain pipeline therapeutics constitutes close to 132 molecules. Out of which approximately 118 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 16, 15, 1, 56, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 2 molecules, respectively.

Our latest report Chronic Pain – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Acadia Pharmaceuticals Inc.
Adynxx, Inc.
Allergan Plc
Amorsa Therapeutics Inc.
arGEN-X BV
Asana BioSciences, LLC
AskAt Inc.
Astraea Therapeutics, LLC
Axsome Therapeutics, Inc.
BioDelivery Sciences International, Inc.
Biogen Inc
Bionomics Limited
Camurus AB
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
ChironWells GmbH
Collegium Pharmaceutical, Inc.
Crinetics Pharmaceuticals, Inc.
Cyclenium Pharma, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dompe Farmaceutici S.p.A.
Echo Pharmaceuticals B.V.
Egalet Corporation
Eli Lilly and Company
Elite Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
Grunenthal GmbH
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Johnson & Johnson
Kareus Therapeutics, SA
KPI Therapeutics, Inc.
Kymab Limited
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Lpath, Inc.
MD Biosciences GmbH
Merck & Co., Inc.
Moberg Pharma AB
Mundipharma International Ltd
Nanomerics Ltd
Nektar Therapeutics
Neura Therapeutik, LLC
Orion Oyj
Pacira Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
PeriphaGen, Inc.
Pfizer Inc.
Phosphagenics Limited
Prismic Pharmaceuticals, Inc.
Purdue Pharma LP
Relmada Therapeutics, Inc.
Ribomic Inc.
Sea4Us
Shulov Innovative Science Ltd.
Synactix Pharmaceuticals, Inc.
Syntrix Biosystems, Inc.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd.
Trevena, Inc.
Voyager Therapeutics, Inc.
Yooyoung Pharmaceutical Co., Ltd.
Zynerba Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll